The c-MET oncoprotein: Function, mechanisms of degradation and its targeting by novel anti-cancer agents.

Park, Kyung Chan; Richardson, Des R

Park, Kyung Chan; Richardson, Des R.

Afiliação

Park KC; Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, New South Wales 2006, Australia.
Richardson DR; Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, New South Wales 2006, Australia,; Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Centre for Cancer Cell Biology, Griffith University, Griffith Institute of Drug Discovery, Nathan, Brisbane, Queensland, Australia. Electronic address: d.richardson@griffith.edu.au.

Biochim Biophys Acta Gen Subj ; 1864(10): 129650, 2020 10.

Article em En | MEDLINE | ID: mdl-32522525

Assuntos

Antineoplásicos/farmacologia; Neoplasias/tratamento farmacológico; Neoplasias/metabolismo; Proteólise/efeitos dos fármacos; Proteínas Proto-Oncogênicas c-met/metabolismo; Animais; Antineoplásicos/química; Antineoplásicos Imunológicos/química; Antineoplásicos Imunológicos/farmacologia; Progressão da Doença; Descoberta de Drogas; Humanos; Terapia de Alvo Molecular; Neoplasias/genética; Proteínas Proto-Oncogênicas c-met/análise; Proteínas Proto-Oncogênicas c-met/genética; Tiossemicarbazonas/química; Tiossemicarbazonas/farmacologia

Palavras-chave

Cancer therapeutics; Degradation; Receptor tyrosine kinase; Thiosemicarbazones; c-MET

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas c-met / Proteólise / Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google